Received: 5.3.11
First Name: David
Last Name: Hodgson
Institution: Princess Margaret Hospital
Address 1: 610 University Ave
Address 2:
City: Toronto
State/Province: Ontario
Country: Canada
Zip: M5R1L5
Phone: (416) 946-2919
Alternate Phone:
Email: david.hodgson@rmp.uhn.on.ca

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes
The specific aims are clear and focused.: Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

---

Project Title: Development of Radiobiologic Models of Second Cancer Risk for Childhood Cancer Patients Treated with Radiation Therapy.
Planned research population (eligibility criteria): Hodgkin lymphoma patients aged 13+ treated with thoracic RT.
Proposed specific aims: 1. to reconstruct 3D normal tissue dosimetry on a sample of HL patients treated with thoracic RT. 2. To apply radiobiologic models of SC risk to this dosimetry and to compare estimated risk with observed risk. 3. to modify models and retest on a test set to create a validated model of SC risk that can be used in modern RT planning systems
Will the project require non-CCSS funding to complete?: Yes
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?: Canadian Institutes for Health Research Deadline for application JUNE 1

Does this project require contact of CCSS study subjects for . . .

Additional self-reported information: No
Biological Samples: No
Medical record data: Yes
If yes to any of the above, please briefly describe.: We would like RT dosimetry data, and SC outcome data

---

What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy: Primary
Chronic Disease:
Psychology / Neuropsychology:
Genetics:
Cancer Control:
Epidemiology / Biostatistics: Secondary

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

Late mortality:
Second Malignancy: Primary

Health Behaviors

Tobacco:
Alcohol:
Physical activity:
Medical screening:
Other:
If other, please specify:

Psychosocial

Insurance:
Marriage:
Education:
Employment:
Other:
If other, please specify:

Medical conditions

Hearing/Vision/Speech:
Hormonal systems:
Heart and vascular:
Respiratory:
Digestive:
Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

Medications

Describe medications:

Pregnancy and offspring:
Family History:

Psychologic/Quality of Life

BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

Chronic conditions (CTCAE v3):
Health status:

Demographic

Age: Secondary
Race:
Sex: Secondary
Others:
If others, please specify:

Cancer treatment

Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery:

Anticipated sources of statistical support

CCSS Statistical Center:
Local institutional statistician: Yes
If local, please provide the name(s) and contact information of the statistician(s) to be involved.: We request formal collaboration with Marilynn Stovall (I have discussed this with her) and would value the input/collaboration of any other appropriate CCSS

investigator (eg. Dr. Armstrong, Dr Oeffinger)
Will this project utilize CCSS biologic samples?: No

If yes, which of the following?

Buccal cell DNA:
Peripheral blood:
Lymphoblastoid cell lines:
Second malignancy pathology samples:
Other requiring collection of samples:
If other, please explain:

Other general comments: